1. bookVolume 72 (2022): Issue 2 (June 2022)
Journal Details
First Published
25 Mar 2014
Publication timeframe
4 times per year
access type Open Access

Reduction in Glomerular and Renal Tubular Damage in Kidneys of Diabetic Rats Supplemented with Alpha-Lipoic Acid

Published Online: 04 Jul 2022
Volume & Issue: Volume 72 (2022) - Issue 2 (June 2022)
Page range: 207 - 223
Received: 21 Dec 2021
Accepted: 27 Apr 2022
Journal Details
First Published
25 Mar 2014
Publication timeframe
4 times per year

Chronic hyperglycemia caused by diabetes results in systemic damage to the body, and the kidney ends up being the target of tissue damage. The use of antioxidants such as alpha-lipoic acid (ALA) has been shown to improve clinical and biochemical parameters in diabetic patients as they help in the prevention of oxidative stress. The present study aimed to undertake a comparative evaluation of the renal morphology of normal and diabetes-induced Wistar rats supplemented with ALA. The experiment had 4 experimental groups (n=7): a control group and a diabetic group that were fed commercial food; an alpha-lipoic group and an alpha-lipoic diabetic group that received the ALA supplement. Diabetes was induced with a single intraperitoneal injection of alloxane monohydrate administered after fasting. After 60 days of the experiment, the kidneys were excised to study the histomorphometric and stereological parameters of the glomeruli and renal tubules and the immunohistochemical parameters with a podocyte count. In the evaluation, the ALA promoted improvement in all of the relevant parameters of the glomerular areas and attenuation of tubular lesions of diabetic animals (p<0.001). Supplementation with ALA also showed beneficial effects in diabetic animals, such as reducing hyperglycemia and the damage promoted by oxidative stress alongside promoting a protective effect on the renal parenchyma. The reduction of glomerular and tubular damage delayed the advance of diabetic nephropathy and its complications, preventing renal failure in diabetic groups.


1. Gilor C, Niessen S, Furrow E, DiBartola S: What’s in a name? Classification of diabetes mellitus in veterinary medicine and why it matters. J Vet Intern Med 2016, 30(4):927-940.10.1111/jvim.14357 Search in Google Scholar

2. Anthony RM, MacLeay JM, Jewell DE, Brejda JJ, Gross KL: Alpha-lipoic acid is an effective nutritive antioxidant for healthy adult dogs. Animals 2021, 11:274.10.3390/ani11020274 Search in Google Scholar

3. Sicree R: The global burden of diabetes. International Diabetes Federation, 2003, 43. Search in Google Scholar

4. Ilatovskaya DV, Levchenko V, Lowing A, Shuyskiy LS, Palygin O, Staruschenko A: Podocyte injury in diabetic nephropathy: implications of angiotensin II–dependent activation of TRPC channels. Sci Rep 2015, 5(1):1-10.10.1038/srep17637 Search in Google Scholar

5. Nelson RW, Couto CG: Disorders of the endocrinal pancreas. 6th ed. Small Animal Internal Medicine. 2019: Elsevier Health Sciences. Search in Google Scholar

6. Vora J, Ibrahim H: Clinical manifestations and natural history of diabetic nephropathy, in Comprehensive Clinical Nephrology 2003, Elsevier Limited: Spain. 425-437. Search in Google Scholar

7. Sangwan P, Khanna K: Consistency of Rat model for diabetic nephropathy. IJAR 2015, 1(9):157-159. Search in Google Scholar

8. Group G: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349(9069):1857-1863.10.1016/S0140-6736(96)11445-8 Search in Google Scholar

9. Luis-Rodríguez D, Martínez-Castelao A, Górriz JL,De-Álvaro F, Navarro-González JF: Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J Diabetes 2012, 3(1):7.10.4239/wjd.v3.i1.7325853622253941 Search in Google Scholar

10. Susztak K, Raff AC, Schiffer M, Böttinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006, 55(1):225-233.10.2337/diabetes.55.01.06.db05-0894 Search in Google Scholar

11. Riella MC: Diabetes Renal Disease, in Principles of nephrology and water-electrolyte imbalance. 2018, 1558-1667. Search in Google Scholar

12. Papadopoulou-Marketou N, Paschou SA, Marketos N, Adamidi S, Adamidis S, Kanaka-Gantenbein C: Diabetic nephropathy in type 1 diabetes. Minerva Med 2017, 109(3):218-228.10.23736/S0026-4806.17.05496-929205998 Search in Google Scholar

13. Slaughter TN, Paige A, Spires D, KojimaN, Kyle PB, Garrett MR, Roman RJ, Williams JM: Characterization of the development of renal injury in Type-1 diabetic Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 2013, 305(7):R727-R734.10.1152/ajpregu.00382.2012379880323926133 Search in Google Scholar

14. Kouzi SA, Yang S, Nuzum DS, Dirks-Naylor AJ: Natural supplements for improving insulin sensitivity and glucose uptake in skeletal muscle. Front Biosci (Elite Ed), 2015, 7(1):94-106. Search in Google Scholar

15. Kamenova P: Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones (Athens) 2006, 5(4):251.10.14310/horm.2002.1119117178700 Search in Google Scholar

16. Moini H, Tirosh O, Park YC, Cho KJ, Packer L: R-α-lipoic acid action on cell redox status, the insulin receptor, and glucose uptake in 3T3-L1 adipocytes. Arch Biochem Biophys 2002, 397(2):384-391.10.1006/abbi.2001.268011795898 Search in Google Scholar

17. Corrêa LBNS, da Costa CAS, Ribas JAS, Boaventura GT, Chagas MA: Antioxidant action of alpha lipoic acid on the testis and epididymis of diabetic rats: morphological, sperm and immunohistochemical evaluation. Int Braz J Urol 2019, 45(4):815-824.10.1590/s1677-5538.ibju.2018.0774 Search in Google Scholar

18. Bilska A, Wlodek L: Lipoic acid-the drug of the future. Pharmacol Rep 2005, 57(5):570-577. Search in Google Scholar

19. Ansar H, Mazloom Z, Kazemi F, Hejazi N: Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. Saudi Med J 2011, 32(6):584-588. Search in Google Scholar

20. Berkson BM, Rubin DM, Berkson AJ: Revisiting the ALA/N (α-Lipoic Acid/Low-Dose Naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther 2009, 8(4):416-422.10.1177/153473540935208220042414 Search in Google Scholar

21. Hager K, Kenklies M, McAfoose J: Alpha-lipoic acid as a new treatment option for Alzheimer’s disease--a 48 months follow-up analysis. Alter Med Rev 2008, 13(1):74-75.10.1007/978-3-211-73574-9_2417982894 Search in Google Scholar

22. Ramos CSCB, Silva VAPD, Corrêa LBNS, Abboud RS, Boaventura GT, Chagas MA: Long-Term Alpha-Lipoic Acid (ALA) Antioxidant Therapy Reduces Damage in the Cardiovascular System of Streptozotocin-Induced Diabetic Rats. J Diet Suppl 2021, 22:1-15.10.1080/19390211.2021.200429034806528 Search in Google Scholar

23. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M: Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 2003, 14(suppl 3):S250-S253.10.1097/01.ASN.0000077412.07578.4412874441 Search in Google Scholar

24. Tankova T, Koev D, Dakovska L: Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study). Rom J Inter Med 2004, 42(2):457-464. Search in Google Scholar

25. Mittermayer F, Pleiner J, Francesconi M, Wolzt M: Treatment with α-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus. Translational Res 2010, 155(1):6-9.10.1016/j.trsl.2009.08.00420004356 Search in Google Scholar

26. de Souza Abboud R, Chagas MA, de Amorim Ribeiro IC, Corrêa LBNS, Lange RM: A modified protocol of the alloxan technique for the induction of diabetes mellitus in Wistar rats. Med Veterinária (UFRPE) 2020, 14(4):315-318.10.26605/medvet-v14n4-2410 Search in Google Scholar

27. Aguirre-Arias MV, Velarde V, Moreno RD: Effects of ascorbic acid on spermatogenesis and sperm parameters in diabetic rats. Cell Tissue Res 2017, 370(2):305-317.10.1007/s00441-017-2660-628770381 Search in Google Scholar

28. Mohasseb M, Ebied S, Yehia MA, Hussein N: Testicular oxidative damage and role of combined antioxidant supplementation in experimental diabetic rats. J Physiol Biochem 2011, 67(2):185-194.10.1007/s13105-010-0062-221184211 Search in Google Scholar

29. Scherle W: A simple method for volumetry of organs in quantitative stereology. Mikroskopie 1970, 26:57-60. Search in Google Scholar

30. Bagetti-Filho HJ, Sampaio FJ, Marques RG, Pereira-Sampaio MA: Different from renal artery only clamping, artery and vein clamping causes a significant reduction in number of rat glomeruli during warm ischemia. J Endourol 2012, 26(10):1335-1339.10.1089/end.2012.016622612865 Search in Google Scholar

31. Bancroft J, Layton C: The Hematoxylin and eosin In: Suvarna S. Theory Practice of histological techniques., 7th ed edn Philadelphia: Churchill Livingstone of El Sevier, Philadelphia: Churchill Livingstone of El Sevier, 2013. Search in Google Scholar

32. de Oliveira Ramos C, Nardeli CR, Campos KKD, Pena KB, Machado DF, Bandeira ACB, de Paula Costa G, Talvani A, Bezerra FS: The exposure to formaldehyde causes renal dysfunction, inflammation and redox imbalance in rats. Exp Toxicol Pathol 2017, 69(6):367-372.10.1016/j.etp.2017.02.00828336174 Search in Google Scholar

33. Chen J, Chen Y, Luo Y, Gui D, Huang J, He D: Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats. Eur J Pharmacol 2014. 736:86-94.10.1016/j.ejphar.2014.04.03724809932 Search in Google Scholar

34. Tunçdemir M, Öztürk M: The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy. Acta Histochem 2011, 113(8):826-832.10.1016/j.acthis.2010.12.00321269661 Search in Google Scholar

35. Su J, Li SJ, Chen ZH, Zeng CH, Zhou H, Li LS, Liu ZH: Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms’ tumor-1 protein used as a podocyte marker. Diabetes Res Clin Pract 2010, 87(2):167-175.10.1016/j.diabres.2009.10.02219969384 Search in Google Scholar

36. Iseki K, Ikemiya Y, Kinjo K, Iseki C, Takishita S: Prevalence of high fasting plasma glucose and risk of developing end-stage renal disease in screened subjects in Okinawa, Japan. J Clin Exp Nephrol 2004, 8(3):250-256.10.1007/s10157-004-0293-z15480903 Search in Google Scholar

37. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE: Functional and structural changes in the kidney in the early stages of obesity. J Am Societ Nephrol 2001, 12(6):1211-1217.10.1681/ASN.V126121111373344 Search in Google Scholar

38. Singh H, Singh R, Arora R, Mannan R, Buttar HS, Arora S, Singh B: Protective role of Phyllanthus fraternus in alloxan-induced diabetes in rats. J Ayurveda Integr Medicine 2020, 11(4):391-398.10.1016/j.jaim.2019.09.008777249632088092 Search in Google Scholar

39. Winiarska, K, Malinska D, Szymanski K, Dudziak M, Bryla J: Lipoic acid ameliorates oxidative stress and renal injury in alloxan diabetic rabbits. Biochimie 2008, 90(3):450-459.10.1016/j.biochi.2007.11.01018157951 Search in Google Scholar

40. Behrend E, Holford A, Lathan P, Rucinsky R, Schulman R: 2018 AAHA diabetes management guidelines for dogs and cats. J Am Animal Hospit Assoc 2018, 54(1):1-21.10.5326/JAAHA-MS-682229314873 Search in Google Scholar

41. Fracassi F, Ettinger S: Canine diabetes mellitus, in Textbook of Veterinary Internal Medicine. 2017, Elsevier: St. Louis, USA. p. 1767-81. Search in Google Scholar

42. Davison LJ: Canine diabetes mellitus, in BSAVA Manual of Canine and Feline Endocrinology. 2012, British Small Animal Veterinary Association.10.22233/9781905319893.12 Search in Google Scholar

43. Golbidi S, Alireza Ebadi S, Laher I: Antioxidants in the treatment of diabetes. Curr Diabetes Rev 2011, 7(2):106-125.10.2174/15733991179494072921294707 Search in Google Scholar

44. Seo EY, Ha AW, Kim WK: α-Lipoic acid reduced weight gain and improved the lipid profile in rats fed with high fat diet. Nutr Res Pract 2012, 6(3):195-200.10.4162/nrp.2012.6.3.195339578322808342 Search in Google Scholar

45. Kayhan Kuştepe E, Bahar L, Zayman E, Sucu N, Gül S, Gül M: A light microscopic investigation of the renoprotective effects of α-lipoic acid and α-tocopherol in an experimental diabetic rat model. Biotech Histochem 2020, 95(4):305-316.10.1080/10520295.2019.169594232013590 Search in Google Scholar

46. Feng B, Yan XF, Xue JL, Xu L, Wang H: The protective effects of α-lipoic acid on kidneys in type 2 diabetic Goto-Kakisaki rats via reducing oxidative stress. Int J Mol Sci 2013, 14(4):6746-6756.10.3390/ijms14046746364566323531536 Search in Google Scholar

47. Portari GV, Moraes RCM, Deminice R, Orsatti FL, Merino S: Effects of the supplementation with alpha-lipoic acid on muscular antioxidant biomarkers of trained mice. Med Exp 2017, 4.10.5935/MedicalExpress.2017.01.05 Search in Google Scholar

48. Turkyilmaz IB, Bilgin Sokmen B, Yanardag R: Alpha lipoic acid prevents brain injury in rats administered with valproic acid. J Biochem Molecul Toxicol 2020, 34(11):e22580.10.1002/jbt.2258032662911 Search in Google Scholar

49. Schnackenberg CG, Wilcox CS: The SOD mimetic tempol restores vasodilation in afferent arterioles of experimental diabetes. Kidney Int 2001, 59(5):1859-1864.10.1046/j.1523-1755.2001.0590051859.x11318957 Search in Google Scholar

50. Huang HC, Preisig PA: G1 kinases and transforming growth factor-β; signaling are associated with a growth pattern switch in diabetes-induced renal growth. Kidney Int 2000, 58(1):162-172.10.1046/j.1523-1755.2000.00151.x10886561 Search in Google Scholar

51. Van Buren PN, Toto R: Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis 2011, 18(1):28-41.10.1053/j.ackd.2010.10.003322101421224028 Search in Google Scholar

52. Jheng HF, Hirotsuka M, Goto T, Shibata M, Matsumura Y, Kawada T: Dietary low-fat soy milk powder retards diabetic nephropathy progression via inhibition of renal fibrosis and renal inflammation. Mol Nutr Food Res 2017, 61(3):1600461.10.1002/mnfr.20160046127748993 Search in Google Scholar

53. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999, 56(5):1627-1637.10.1046/j.1523-1755.1999.00721.x10571771 Search in Google Scholar

54. Cunningham JG, Klein BG: Veterinary physiology. 2007: Saunders Elsevier Philadelphia. Search in Google Scholar

55. Garovic VD, Wagner SJ, Turner ST, Rosenthal DW, Watson WJ, Brost BC, Rose CH, Gavrilova L, Craigo P, Bailey KR, Achenbach J, Schiffer M, Grande JP: Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007, 196(4):320.e1-7.10.1016/j.ajog.2007.02.00717403404 Search in Google Scholar

56. Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, Takeuchi M, Fukami K, Yamagishi S: Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product–induced protein arginine methyltranferase-1 expression. Am J Pathol 2013, 182(1):132-141.10.1016/j.ajpath.2012.09.01623159951 Search in Google Scholar

57. Siu B, Saha J, Smoyer WE, Sullivan KA, Brosius FC: Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment. BMC Nephrol 2006, 7(1):1-11.10.1186/1471-2369-7-6143587616539708 Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo